Wealthspire Advisors (Maryland)’s Stemline Therapeutics, Inc. STML Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,470	Closed	-$19K	–	2409
2019 Q1	$19K	Hold	1,470	–	–	﹤0.01%	1310
2018 Q4	$14K	Hold	1,470	–	–	﹤0.01%	1360
2018 Q3	$24K	Hold	1,470	–	–	﹤0.01%	1241
2018 Q2	$24K	Buy	+1,470	New	+$26.2K	﹤0.01%	1250
2018 Q1	–	Sell	-1,000	Closed	-$16K	–	2705
2017 Q4	$16K	Hold	1,000	–	–	﹤0.01%	1418
2017 Q3	$11K	Buy	+1,000	New	+$9.4K	﹤0.01%	1555

Other funds holding STML

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s STML Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Stemline Therapeutics, Inc. (STML) in Q2 2019, closing a stake of 1,470 shares — an estimated $19K sold.

Wealthspire Advisors (Maryland) first reported a position in STML in Q3 2017 and held it in 6 quarters. The position peaked at $24K in Q3 2018. 96 funds tracked by Wall St. Rank hold STML as of Q2 2019.

Wealthspire Advisors (Maryland) reported no remaining Stemline Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Wealthspire Advisors (Maryland) sold 1,470 Stemline Therapeutics, Inc. shares in Q2 2019, an estimated $19K.
Wealthspire Advisors (Maryland) first reported a position in Stemline Therapeutics, Inc. in Q3 2017 and held it in 6 quarters.
Wealthspire Advisors (Maryland)'s Stemline Therapeutics, Inc. position peaked at $24K in Q3 2018.
96 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.